Health

STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 13:36:25 UTC.

Briefings

STAT reports on GSK's oncology sales growth and a House investigation into pharmacy benefit managers. GSK's oncology sales reached $2.67 billion, a 43% increase from the previous year, though it remains significantly smaller than competitors like Merck. A House committee is auditing three major PBMs for supporting legislation that mandates payment adjustments to retailers.

Key points

• GSK's oncology sales reached $2.67 billion, representing a 43% increase from the prior year.
• A House committee is auditing three major pharmacy benefit managers for supporting legislation requiring payment adjustments to retailers.

Context

STAT+ provides updates on pharmaceutical industry developments, including GSK's oncology performance and regulatory investigations into pharmacy benefit management practices.

Limitations

Evidence covers only oncology sales figures and House committee actions; no specific dates for the audit, no names of audited PBMs beyond the three mentioned, and no details on the legislative bill's provisions.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 14:50:01 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiaaxwal4bsd44ouhilkuqnjogye6pvbaesvkvu75os5riztpp53wq